Generic drugmaker says it was pushed to be paid to delay

Generics UK had “little choice” but to enter into a settlement with GlaxoSmithKline in an alleged pay-for-delay scheme, counsel to the generic drugmaker told the Competition Appeal Tribunal today.

Get unlimited access to all Global Competition Review content